Kewaunee Scientific Revenue declined to $66.32 million in the three months ended July 31, 2026, while Earnings attributable to shareholders fell to $1.706 million, or $0.58 per diluted share. Investors face lower sales and backlog, although gross Margin improved to 29.6% and Operating Activities generated $1.976 million.

Key Highlights

  • Gross profit margin increased to 29.6%, supported by improved performance in the International segment.
  • Order Backlog was $169.0 million at July 31, 2026, down from $205.0 million a year earlier.
  • Net earnings attributable to Kewaunee Scientific shareholders fell to $1.706 million from $3.093 million.

Kewaunee Scientific Corporation (NASDAQ: KEQU) generated $66.32 million of revenue in the three months ended July 31, 2026, down from $71.104 million in the comparable period. Net earnings attributable to Kewaunee Scientific shareholders fell to $1.706 million from $3.093 million, while Diluted Earnings per Share declined to $0.58 from $1.04. Net earnings for the quarter were $1.843 million. The quarter paired weaker sales with lower operating profit, although interest expense also declined. Kewaunee Scientific reported $3.158 million of operating profit, $2.560 million of profit before income taxes and $717,000 of income tax expense.

Revenue And Earnings Decline

Cost of products sold was $46.681 million, compared with $50.174 million in the prior-year period. Gross profit reached $19.639 million versus $20.930 million, while operating expenses increased to $16.481 million from $16.120 million. Other income, net, was $28,000, down from $168,000. Interest expense decreased to $626,000 from $1.058 million, reflecting changes in bank and other borrowings and interest rates. The effective income tax rate was 28.0%, compared with 19.4% in the comparable period. Basic Earnings Per Share were $0.59, down from $1.08. The weighted-average basic share count was 2,880,000, compared with 2,851,000, while diluted weighted-average shares were 2,921,000 versus 2,963,000.

Domestic Demand Weighs On Sales

LPG revenue was $50.868 million, down from $54.352 million, a 6.4% decrease. International revenue was $15.452 million, compared with $16.752 million, a 7.8% decline. Revenue recognized over time totaled $46.559 million, including $31.107 million from LPG and $15.452 million from International. Point-in-time revenue was $19.761 million, all from LPG. The Gross Profit Margin increased to 29.6% of sales from 29.4%. The improvement primarily came from stronger margin performance in the International segment.

Backlog And Cash Movement

The company said demand is difficult to predict because it operates as a subcontractor or supplier to dealers for subcontractors. Operating activities generated $1.976 million of cash during the quarter. The result was primarily driven by operations, a $0.5 million decrease in receivables, a $0.7 million decrease in inventories and a $1.0 million increase in deferred revenue. Those inflows were partly offset by a $3.0 million decrease in Accounts Payable and other accrued expenses and a $1.2 million change in other items, net. Investing activities used $772,000 related to capital expenditures, while financing activities used $2.499 million. Working Capital was $56.716 million at July 31, 2026, compared with $57.046 million at April 30, 2026. The current-assets-to-current-liabilities ratio was 2.2-to-1.0 at both dates.

Kewaunee Scientific said future demand depends on planned laboratory construction projects and the progress of projects already under construction. Its ability to predict demand remains limited.